Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy

DOI record: { "DOI": "10.7759/cureus.56025", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.56025", "author": [ { "affiliation": [], "family": "Kaur", "given": "Baneet", "sequence": "first" }, { "affiliation": [], "family": "Blavo", "given": "Cyril", "sequence": "additional" }, { "affiliation": [], "family": "Parmar", "given": "Mayur S", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 3, 12 ] ], "date-time": "2024-03-12T13:47:21Z", "timestamp": 1710251241000 }, "deposited": { "date-parts": [ [ 2024, 3, 12 ] ], "date-time": "2024-03-12T13:47:27Z", "timestamp": 1710251247000 }, "indexed": { "date-parts": [ [ 2024, 3, 13 ] ], "date-time": "2024-03-13T00:46:32Z", "timestamp": 1710290792242 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 3, 12 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/223832-ivermectin-a-multifaceted-drug-with-a-potential-beyond-anti-parasitic-therapy", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2024, 3, 12 ] ] }, "published-print": { "date-parts": [ [ 2024, 3, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.2183/pjab.87.13", "article-title": "Ivermectin, \"wonder drug\" from Japan: the human use perspective", "author": "Crump A", "doi-asserted-by": "publisher", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci", "key": "ref1", "unstructured": "Crump A, Ōmura S. Ivermectin, \"wonder drug\" from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011, 87:13-28. 10.2183/pjab.87.13", "volume": "87", "year": "2011" }, { "DOI": "10.1093/trstmh/trab114", "article-title": "Broadening the range of use cases for ivermectin - a review of the evidence", "author": "Kositz C", "doi-asserted-by": "publisher", "journal-title": "Trans R Soc Trop Med Hyg", "key": "ref2", "unstructured": "Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M. Broadening the range of use cases for ivermectin - a review of the evidence. Trans R Soc Trop Med Hyg. 2022, 116:201-12. 10.1093/trstmh/trab114", "volume": "116", "year": "2022" }, { "article-title": "Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials", "author": "De Sole G", "journal-title": "Bull World Health Organ", "key": "ref3", "unstructured": "De Sole G, Remme J, Awadzi K, et al.. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ. 1989, 67:707-19.", "volume": "67", "year": "1989" }, { "DOI": "10.1093/infdis/156.3.463", "article-title": "Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis", "author": "White AT", "doi-asserted-by": "publisher", "journal-title": "J Infect Dis", "key": "ref4", "unstructured": "White AT, Newland HS, Taylor HR, et al.. Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis. J Infect Dis. 1987, 156:463-70. 10.1093/infdis/156.3.463", "volume": "156", "year": "1987" }, { "DOI": "10.1016/s0140-6736(85)91496-5", "article-title": "Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement", "author": "Lariviere M", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref5", "unstructured": "Lariviere M, Vingtain P, Aziz M, et al.. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet. 1985, 2:174-7. 10.1016/s0140-6736(85)91496-5", "volume": "2", "year": "1985" }, { "DOI": "10.1016/0035-9203(86)90262-2", "article-title": "A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis", "author": "Diallo S", "doi-asserted-by": "publisher", "journal-title": "Trans R Soc Trop Med Hyg", "key": "ref6", "unstructured": "Diallo S, Aziz MA, Lariviere M, et al.. A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis. Trans R Soc Trop Med Hyg. 1986, 80:927-34. 10.1016/0035-9203(86)90262-2", "volume": "80", "year": "1986" }, { "DOI": "10.1080/00034983.1986.11812044", "article-title": "The chemotherapy of onchocerciasis. XI. A double-blind comparative study of ivermectin, diethylcarbamazine and placebo in human onchocerciasis in northern Ghana", "author": "Awadzi K", "doi-asserted-by": "publisher", "journal-title": "Ann Trop Med Parasitol", "key": "ref7", "unstructured": "Awadzi K, Dadzie KY, Schulz-Key H, Gilles HM, Fulford AJ, Aziz MA. The chemotherapy of onchocerciasis. XI. A double-blind comparative study of ivermectin, diethylcarbamazine and placebo in human onchocerciasis in northern Ghana. Ann Trop Med Parasitol. 1986, 80:433-42. 10.1080/00034983.1986.11812044", "volume": "80", "year": "1986" }, { "DOI": "10.1056/NEJM198507183130301", "article-title": "Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis", "author": "Greene BM", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref8", "unstructured": "Greene BM, Taylor HR, Cupp EW, et al.. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med. 1985, 313:133-8. 10.1056/NEJM198507183130301", "volume": "313", "year": "1985" }, { "DOI": "10.1038/371707a0", "article-title": "Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans", "author": "Cully DF", "doi-asserted-by": "publisher", "journal-title": "Nature", "key": "ref9", "unstructured": "Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, Arena JP. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature. 1994, 371:707-11. 10.1038/371707a0", "volume": "371", "year": "1994" }, { "DOI": "10.1152/jn.01234.2006", "article-title": "Dorsal unpaired median neurons of locusta migratoria express ivermectin- and fipronil-sensitive glutamate-gated chloride channels", "author": "Janssen D", "doi-asserted-by": "publisher", "journal-title": "J Neurophysiol", "key": "ref10", "unstructured": "Janssen D, Derst C, Buckinx R, Van den Eynden J, Rigo JM, Van Kerkhove E. Dorsal unpaired median neurons of locusta migratoria express ivermectin- and fipronil-sensitive glutamate-gated chloride channels. J Neurophysiol. 2007, 97:2642-50. 10.1152/jn.01234.2006", "volume": "97", "year": "2007" }, { "DOI": "10.1152/jn.00466.2009", "article-title": "Cys-loop ligand-gated chloride channels in dorsal unpaired median neurons of Locusta migratoria", "author": "Janssen D", "doi-asserted-by": "publisher", "journal-title": "J Neurophysiol", "key": "ref11", "unstructured": "Janssen D, Derst C, Rigo JM, Van Kerkhove E. Cys-loop ligand-gated chloride channels in dorsal unpaired median neurons of Locusta migratoria. J Neurophysiol. 2010, 103:2587-98. 10.1152/jn.00466.2009", "volume": "103", "year": "2010" }, { "DOI": "10.1124/mol.108.053363", "article-title": "An ivermectin-sensitive glutamate-gated chloride channel from the parasitic nematode Haemonchus contortus", "author": "McCavera S", "doi-asserted-by": "publisher", "journal-title": "Mol Pharmacol", "key": "ref12", "unstructured": "McCavera S, Rogers AT, Yates DM, Woods DJ, Wolstenholme AJ. An ivermectin-sensitive glutamate-gated chloride channel from the parasitic nematode Haemonchus contortus. Mol Pharmacol. 2009, 75:1347-55. 10.1124/mol.108.053363", "volume": "75", "year": "2009" }, { "DOI": "10.1073/pnas.1011983107", "article-title": "Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi", "author": "Moreno Y", "doi-asserted-by": "publisher", "journal-title": "Proc Natl Acad Sci U S A", "key": "ref13", "unstructured": "Moreno Y, Nabhan JF, Solomon J, Mackenzie CD, Geary TG. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc Natl Acad Sci U S A. 2010, 107:20120-5. 10.1073/pnas.1011983107", "volume": "107", "year": "2010" }, { "DOI": "10.1016/j.bcp.2011.10.010", "article-title": "Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line", "author": "Ménez C", "doi-asserted-by": "publisher", "journal-title": "Biochem Pharmacol", "key": "ref14", "unstructured": "Ménez C, Mselli-Lakhal L, Foucaud-Vignault M, Balaguer P, Alvinerie M, Lespine A. Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line. Biochem Pharmacol. 2012, 83:269-78. 10.1016/j.bcp.2011.10.010", "volume": "83", "year": "2012" }, { "DOI": "10.1016/0092-8674(94)90212-7", "article-title": "Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs", "author": "Schinkel AH", "doi-asserted-by": "publisher", "journal-title": "Cell", "key": "ref15", "unstructured": "Schinkel AH, Smit JJ, van Tellingen O, et al.. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994, 77:491-502. 10.1016/0092-8674(94)90212-7", "volume": "77", "year": "1994" }, { "DOI": "10.1016/j.ijantimicag.2019.05.003", "article-title": "Ivermectin: from theory to clinical application", "author": "Ashour DS", "doi-asserted-by": "publisher", "journal-title": "Int J Antimicrob Agents", "key": "ref16", "unstructured": "Ashour DS. Ivermectin: from theory to clinical application. Int J Antimicrob Agents. 2019, 54:134-42. 10.1016/j.ijantimicag.2019.05.003", "volume": "54", "year": "2019" }, { "DOI": "10.1002/14651858.CD012994", "article-title": "Ivermectin and permethrin for treating scabies", "author": "Rosumeck S", "doi-asserted-by": "publisher", "journal-title": "Cochrane Database Syst Rev", "key": "ref17", "unstructured": "Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018, 4:CD012994. 10.1002/14651858.CD012994", "volume": "4", "year": "2018" }, { "DOI": "10.1007/s13555-018-0249-y", "article-title": "Topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations", "author": "Ebbelaar CC", "doi-asserted-by": "publisher", "journal-title": "Dermatol Ther (Heidelb)", "key": "ref18", "unstructured": "Ebbelaar CC, Venema AW, Van Dijk MR. Topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb). 2018, 8:379-87. 10.1007/s13555-018-0249-y", "volume": "8", "year": "2018" }, { "DOI": "10.2174/138920112800399248", "article-title": "Ivermectin in human medicine, an overview of the current status of its clinical applications", "author": "González P", "doi-asserted-by": "publisher", "journal-title": "Curr Pharm Biotechnol", "key": "ref19", "unstructured": "González P, González FA, Ueno K. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012, 13:1103-9. 10.2174/138920112800399248", "volume": "13", "year": "2012" }, { "DOI": "10.1186/s13071-020-04512-5", "article-title": "High concentrations of membrane-fed ivermectin are required for substantial lethal and sublethal impacts on Aedes aegypti", "author": "Hadlett M", "doi-asserted-by": "publisher", "journal-title": "Parasit Vectors", "key": "ref20", "unstructured": "Hadlett M, Nagi SC, Sarkar M, Paine MJ, Weetman D. High concentrations of membrane-fed ivermectin are required for substantial lethal and sublethal impacts on Aedes aegypti. Parasit Vectors. 2021, 14:9. 10.1186/s13071-020-04512-5", "volume": "14", "year": "2021" }, { "DOI": "10.1186/s13063-023-07098-2", "article-title": "BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings", "author": "Chaccour C", "doi-asserted-by": "publisher", "journal-title": "Trials", "key": "ref21", "unstructured": "Chaccour C, Casellas A, Hammann F, et al.. BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. Trials. 2023, 24:128. 10.1186/s13063-023-07098-2", "volume": "24", "year": "2023" }, { "DOI": "10.1002/ps.7217", "article-title": "Potential of ivermectin as an active ingredient of the attractive toxic sugar baits against the Indian malaria vectors Anopheles culicifacies and Anopheles stephensi", "author": "Kumar G", "doi-asserted-by": "publisher", "journal-title": "Pest Manag Sci", "key": "ref22", "unstructured": "Kumar G, Pasi S, Yadav CP, Kaur J, Sharma A. Potential of ivermectin as an active ingredient of the attractive toxic sugar baits against the Indian malaria vectors Anopheles culicifacies and Anopheles stephensi. Pest Manag Sci. 2023, 79:474-80. 10.1002/ps.7217", "volume": "79", "year": "2023" }, { "DOI": "10.1128/aac.01730-22", "article-title": "Activity of ivermectin and its metabolites against asexual blood stage Plasmodium falciparum and its interactions with antimalarial drugs", "author": "Yipsirimetee A", "doi-asserted-by": "publisher", "journal-title": "Antimicrob Agents Chemother", "key": "ref23", "unstructured": "Yipsirimetee A, Tipthara P, Hanboonkunupakarn B, et al.. Activity of ivermectin and its metabolites against asexual blood stage Plasmodium falciparum and its interactions with antimalarial drugs. Antimicrob Agents Chemother. 2023, 67:e0173022. 10.1128/aac.01730-22", "volume": "67", "year": "2023" }, { "DOI": "10.1186/s12936-023-04624-0", "article-title": "Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes", "author": "Kern C", "doi-asserted-by": "publisher", "journal-title": "Malar J", "key": "ref24", "unstructured": "Kern C, Müller P, Chaccour C, Liechti ME, Hammann F, Duthaler U. Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes. Malar J. 2023, 22:194. 10.1186/s12936-023-04624-0", "volume": "22", "year": "2023" }, { "DOI": "10.3389/fphar.2023.1169916", "article-title": "Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis", "author": "Xiao W", "doi-asserted-by": "publisher", "journal-title": "Front Pharmacol", "key": "ref25", "unstructured": "Xiao W, Chen M, Wang B, et al.. Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis. Front Pharmacol. 2023, 14:1169916. 10.3389/fphar.2023.1169916", "volume": "14", "year": "2023" }, { "DOI": "10.1016/j.phrs.2020.105207", "article-title": "Ivermectin, a potential anticancer drug derived from an antiparasitic drug", "author": "Tang M", "doi-asserted-by": "publisher", "journal-title": "Pharmacol Res", "key": "ref26", "unstructured": "Tang M, Hu X, Wang Y, et al.. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021, 163:105207. 10.1016/j.phrs.2020.105207", "volume": "163", "year": "2021" }, { "DOI": "10.1177/09603271221143693", "article-title": "Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma", "author": "Hu B", "doi-asserted-by": "publisher", "journal-title": "Hum Exp Toxicol", "key": "ref27", "unstructured": "Hu B, Tan H, Yu L, Liao Q, Guo W. Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma. Hum Exp Toxicol. 2022, 41:9603271221143693. 10.1177/09603271221143693", "volume": "41", "year": "2022" }, { "DOI": "10.3390/diseases11010049", "article-title": "Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells", "author": "Jawad MJ", "doi-asserted-by": "publisher", "journal-title": "Diseases", "key": "ref28", "unstructured": "Jawad MJ, Richardson A. Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells. Diseases. 2023, 11:10.3390/diseases11010049", "volume": "11", "year": "2023" }, { "DOI": "10.1007/s00432-023-04829-5", "article-title": "Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway", "author": "Samy A", "doi-asserted-by": "publisher", "journal-title": "J Cancer Res Clin Oncol", "key": "ref29", "unstructured": "Samy A, Hussein MA, Munirathinam G. Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway. J Cancer Res Clin Oncol. 2023, 149:9085-104. 10.1007/s00432-023-04829-5", "volume": "149", "year": "2023" }, { "DOI": "10.1590/1519-6984.258325", "article-title": "Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols", "author": "Marques LL", "doi-asserted-by": "publisher", "journal-title": "Braz J Biol", "key": "ref30", "unstructured": "Marques LL, Beneti SC, Pinzon C, Cardoso FA. Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols. Braz J Biol. 2022, 84:e258325. 10.1590/1519-6984.258325", "volume": "84", "year": "2022" }, { "DOI": "10.3238/arztebl.m2021.0296", "article-title": "Scabies: epidemiology, diagnosis, and treatment", "author": "Sunderkötter C", "doi-asserted-by": "publisher", "journal-title": "Dtsch Arztebl Int", "key": "ref31", "unstructured": "Sunderkötter C, Wohlrab J, Hamm H. Scabies: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int. 2021, 118:695-704. 10.3238/arztebl.m2021.0296", "volume": "118", "year": "2021" }, { "DOI": "10.3390/life12101598", "article-title": "Increased scabies incidence at the beginning of the 21st century: what do reports from Europe and the world show?", "author": "Aždajić MD", "doi-asserted-by": "publisher", "journal-title": "Life (Basel)", "key": "ref32", "unstructured": "Aždajić MD, Bešlić I, Gašić A, Ferara N, Pedić L, Lugović-Mihić L. Increased scabies incidence at the beginning of the 21st century: what do reports from Europe and the world show?. Life (Basel). 2022, 12:10.3390/life12101598", "volume": "12", "year": "2022" }, { "DOI": "10.1080/22221751.2020.1754136", "article-title": "Trends in prevalence and incidence of scabies from 1990 to 2017: findings from the global Burden of disease study 2017", "author": "Zhang W", "doi-asserted-by": "publisher", "journal-title": "Emerg Microbes Infect", "key": "ref33", "unstructured": "Zhang W, Zhang Y, Luo L, et al.. Trends in prevalence and incidence of scabies from 1990 to 2017: findings from the global Burden of disease study 2017. Emerg Microbes Infect. 2020, 9:813-6. 10.1080/22221751.2020.1754136", "volume": "9", "year": "2020" }, { "DOI": "10.1007/978-3-031-26070-4_2", "article-title": "Biology of Sarcoptes scabiei and Its Relevance to Human Scabies: Clinical Symptoms, Treatment, and Management.", "author": "Yotsu RR", "doi-asserted-by": "publisher", "key": "ref34", "unstructured": "Yotsu RR, Yoshizumi J, Izri A. Biology of Sarcoptes scabiei and Its Relevance to Human Scabies: Clinical Symptoms, Treatment, and Management.. Scabies. Fischer K, Chosidow O (ed): Springer, Cham; 2023. 19-34. 10.1007/978-3-031-26070-4_2", "year": "2023" }, { "DOI": "10.1016/j.cger.2023.09.010", "article-title": "Evaluation and management of pruritus and scabies in the elderly population", "author": "Meltan S", "doi-asserted-by": "publisher", "journal-title": "Clin Geriatr Med", "key": "ref35", "unstructured": "Meltan S, Panuganti B, Tarbox M. Evaluation and management of pruritus and scabies in the elderly population. Clin Geriatr Med. 2024, 40:91-116. 10.1016/j.cger.2023.09.010", "volume": "40", "year": "2024" }, { "DOI": "10.1080/09546634.2020.1774489", "article-title": "Loss of efficacy of topical 5% permethrin for treating scabies: an Austrian single-center study", "author": "Meyersburg D", "doi-asserted-by": "publisher", "journal-title": "J Dermatolog Treat", "key": "ref36", "unstructured": "Meyersburg D, Kaiser A, Bauer JW. Loss of efficacy of topical 5% permethrin for treating scabies: an Austrian single-center study. J Dermatolog Treat. 2022, 33:774-7. 10.1080/09546634.2020.1774489", "volume": "33", "year": "2022" }, { "DOI": "10.1111/jdv.18573", "article-title": "Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study", "author": "Meyersburg D", "doi-asserted-by": "publisher", "journal-title": "J Eur Acad Dermatol Venereol", "key": "ref37", "unstructured": "Meyersburg D, Welponer T, Kaiser A, Selhofer S, Tatarski R, Handisurya A, Bauer JW. Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study. J Eur Acad Dermatol Venereol. 2023, 37:160-5. 10.1111/jdv.18573", "volume": "37", "year": "2023" }, { "DOI": "10.1046/j.1525-1470.2001.018001063.x", "article-title": "Topical ivermectin: a new successful treatment for scabies", "author": "Victoria J", "doi-asserted-by": "publisher", "journal-title": "Pediatr Dermatol", "key": "ref38", "unstructured": "Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol. 2001, 18:63-5. 10.1046/j.1525-1470.2001.018001063.x", "volume": "18", "year": "2001" }, { "DOI": "10.1016/j.jaad.2017.09.006", "article-title": "Ivermectin versus permethrin in the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials", "author": "Dhana A", "doi-asserted-by": "publisher", "journal-title": "J Am Acad Dermatol", "key": "ref39", "unstructured": "Dhana A, Yen H, Okhovat JP, Cho E, Keum N, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018, 78:194-8. 10.1016/j.jaad.2017.09.006", "volume": "78", "year": "2018" }, { "article-title": "Treatment of scabies: comparison of ivermectin vs. lindane lotion 1%", "author": "Mohebbipour A", "journal-title": "Acta Dermatovenerol Croat", "key": "ref40", "unstructured": "Mohebbipour A, Saleh P, Goldust M, Amirnia M, Zadeh YJ, Mohamadi RM, Rezaee E. Treatment of scabies: comparison of ivermectin vs. lindane lotion 1%. Acta Dermatovenerol Croat. 2012, 20:251-5.", "volume": "20", "year": "2012" }, { "DOI": "10.1016/j.carres.2023.108887", "article-title": "Carbohydrate derivatives fight against malaria parasite as anti-plasmodial agents", "author": "Singh K", "doi-asserted-by": "publisher", "journal-title": "Carbohydr Res", "key": "ref41", "unstructured": "Singh K, Tripathi RP. Carbohydrate derivatives fight against malaria parasite as anti-plasmodial agents. Carbohydr Res. 2023, 531:108887. 10.1016/j.carres.2023.108887", "volume": "531", "year": "2023" }, { "DOI": "10.1242/jeb.118570", "article-title": "Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae", "author": "Meyers JI", "doi-asserted-by": "publisher", "journal-title": "J Exp Biol", "key": "ref42", "unstructured": "Meyers JI, Gray M, Kuklinski W, et al.. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol. 2015, 218:1478-86. 10.1242/jeb.118570", "volume": "218", "year": "2015" }, { "DOI": "10.1126/scitranslmed.aag2374", "article-title": "Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals", "author": "Bellinger AM", "doi-asserted-by": "publisher", "journal-title": "Sci Transl Med", "key": "ref43", "unstructured": "Bellinger AM, Jafari M, Grant TM, et al.. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016, 8:365ra157. 10.1126/scitranslmed.aag2374", "volume": "8", "year": "2016" }, { "DOI": "10.1016/S0140-6736(18)32321-3", "article-title": "Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial", "author": "Foy BD", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref44", "unstructured": "Foy BD, Alout H, Seaman JA, et al.. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019, 393:1517-26. 10.1016/S0140-6736(18)32321-3", "volume": "393", "year": "2019" }, { "DOI": "10.1016/S0140-6736(19)31663-0", "article-title": "Analysis of the RIMDAMAL trial", "author": "Bradley J", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref45", "unstructured": "Bradley J, Moulton LH, Hayes R. Analysis of the RIMDAMAL trial. Lancet. 2019, 394:1005-6. 10.1016/S0140-6736(19)31663-0", "volume": "394", "year": "2019" }, { "DOI": "10.1016/S0140-6736(19)32139-7", "article-title": "Analysis of the RIMDAMAL trial - Authors' reply", "author": "Foy BD", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref46", "unstructured": "Foy BD, Rao S, Parikh S, Slater HC, Dabiré RK. Analysis of the RIMDAMAL trial - Authors' reply. Lancet. 2019, 394:1006-7. 10.1016/S0140-6736(19)32139-7", "volume": "394", "year": "2019" }, { "DOI": "10.2196/41197", "article-title": "Repeat ivermectin mass drug administrations for malaria control II: protocol for a double-blind, cluster-randomized, placebo-controlled trial for the integrated control of malaria", "author": "Foy BD", "doi-asserted-by": "publisher", "journal-title": "JMIR Res Protoc", "key": "ref47", "unstructured": "Foy BD, Some A, Magalhaes T, et al.. Repeat ivermectin mass drug administrations for malaria control II: protocol for a double-blind, cluster-randomized, placebo-controlled trial for the integrated control of malaria. JMIR Res Protoc. 2023, 12:e41197. 10.2196/41197", "volume": "12", "year": "2023" }, { "article-title": "Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications", "author": "Kircik LH", "journal-title": "J Drugs Dermatol", "key": "ref48", "unstructured": "Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016, 15:325-32.", "volume": "15", "year": "2016" }, { "DOI": "10.1007/s00011-008-8007-8", "article-title": "Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice", "author": "Zhang X", "doi-asserted-by": "publisher", "journal-title": "Inflamm Res", "key": "ref49", "unstructured": "Zhang X, Song Y, Ci X, et al.. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008, 57:524-9. 10.1007/s00011-008-8007-8", "volume": "57", "year": "2008" }, { "DOI": "10.1038/s41429-021-00491-6", "article-title": "The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review", "author": "Zaidi AK", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref50", "unstructured": "Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review. J Antibiot (Tokyo). 2022, 75:60-71. 10.1038/s41429-021-00491-6", "volume": "75", "year": "2022" }, { "DOI": "10.1177/1203475419867611", "article-title": "The role of IL-17 in papulopustular rosacea and future directions", "author": "Amir Ali A", "doi-asserted-by": "publisher", "journal-title": "J Cutan Med Surg", "key": "ref51", "unstructured": "Amir Ali A, Vender R, Vender R. The role of IL-17 in papulopustular rosacea and future directions. J Cutan Med Surg. 2019, 23:635-41. 10.1177/1203475419867611", "volume": "23", "year": "2019" }, { "DOI": "10.1038/s41418-020-00633-7", "article-title": "An aberrant STAT pathway is central to COVID-19", "author": "Matsuyama T", "doi-asserted-by": "publisher", "journal-title": "Cell Death Differ", "key": "ref52", "unstructured": "Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020, 27:3209-25. 10.1038/s41418-020-00633-7", "volume": "27", "year": "2020" }, { "DOI": "10.1111/ijd.16920", "article-title": "Long-term maintenance treatment of rosacea: experts' opinion", "author": "Almeida LM", "doi-asserted-by": "publisher", "journal-title": "Int J Dermatol", "key": "ref53", "unstructured": "Almeida LM, Ianhez M, Dal'Forno T, et al.. Long-term maintenance treatment of rosacea: experts' opinion. Int J Dermatol. 2024, 63:94-101. 10.1111/ijd.16920", "volume": "63", "year": "2024" }, { "DOI": "10.1111/ddg.14849", "article-title": "S2k guideline: Rosacea", "author": "Clanner-Engelshofen BM", "doi-asserted-by": "publisher", "journal-title": "J Dtsch Dermatol Ges", "key": "ref54", "unstructured": "Clanner-Engelshofen BM, Bernhard D, Dargatz S, et al.. S2k guideline: Rosacea. J Dtsch Dermatol Ges. 2022, 20:1147-65. 10.1111/ddg.14849", "volume": "20", "year": "2022" }, { "DOI": "10.1080/09546634.2020.1737636", "article-title": "Pulsed dye laser alone versus its combination with topical ivermectin 1% in treatment of Rosacea: a randomized comparative study", "author": "Osman M", "doi-asserted-by": "publisher", "journal-title": "J Dermatolog Treat", "key": "ref55", "unstructured": "Osman M, Shokeir HA, Hassan AM, Khalifa MA. Pulsed dye laser alone versus its combination with topical ivermectin 1% in treatment of Rosacea: a randomized comparative study. J Dermatolog Treat. 2022, 33:184-90. 10.1080/09546634.2020.1737636", "volume": "33", "year": "2022" }, { "DOI": "10.1080/14656566.2018.1447562", "article-title": "Ivermectin 1% (CD5024) for the treatment of rosacea", "author": "Sahni DR", "doi-asserted-by": "publisher", "journal-title": "Expert Opin Pharmacother", "key": "ref56", "unstructured": "Sahni DR, Feldman SR, Taylor SL. Ivermectin 1% (CD5024) for the treatment of rosacea. Expert Opin Pharmacother. 2018, 19:511-6. 10.1080/14656566.2018.1447562", "volume": "19", "year": "2018" }, { "DOI": "10.1042/BST20200568", "article-title": "Antivirals that target the host IMPα/β1-virus interface", "author": "Martin AJ", "doi-asserted-by": "publisher", "journal-title": "Biochem Soc Trans", "key": "ref57", "unstructured": "Martin AJ, Jans DA. Antivirals that target the host IMPα/β1-virus interface. Biochem Soc Trans. 2021, 49:281-95. 10.1042/BST20200568", "volume": "49", "year": "2021" }, { "DOI": "10.1016/j.bbrc.2020.10.042", "article-title": "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?", "author": "Jans DA", "doi-asserted-by": "publisher", "journal-title": "Biochem Biophys Res Commun", "key": "ref58", "unstructured": "Jans DA, Wagstaff KM. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?. Biochem Biophys Res Commun. 2021, 538:163-72. 10.1016/j.bbrc.2020.10.042", "volume": "538", "year": "2021" }, { "DOI": "10.1128/JVI.00710-20", "article-title": "Inhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin", "author": "King CR", "doi-asserted-by": "publisher", "journal-title": "J Virol", "key": "ref59", "unstructured": "King CR, Tessier TM, Dodge MJ, Weinberg JB, Mymryk JS. Inhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin. J Virol. 2020, 94:10.1128/JVI.00710-20", "volume": "94", "year": "2020" }, { "DOI": "10.1007/s00203-023-03806-3", "article-title": "Ivermectin antiviral activity against Varicellovirus bovinealpha 1: assessment of intracellular drug accumulation in virus-infected cells", "author": "Pérez S", "doi-asserted-by": "publisher", "journal-title": "Arch Microbiol", "key": "ref60", "unstructured": "Pérez S, Miró MV, Verna A, Altamiranda EG, Barcos O, Lanusse C, Lifschitz A. Ivermectin antiviral activity against Varicellovirus bovinealpha 1: assessment of intracellular drug accumulation in virus-infected cells. Arch Microbiol. 2024, 206:78. 10.1007/s00203-023-03806-3", "volume": "206", "year": "2024" }, { "DOI": "10.1016/j.virol.2023.109958", "article-title": "Ivermectin inhibits replication of the malignant catarrhal fever virus alcelaphine herpesvirus 1", "author": "Patho B", "doi-asserted-by": "publisher", "journal-title": "Virology", "key": "ref61", "unstructured": "Patho B, Grant DM, Percival A, Russell GC. Ivermectin inhibits replication of the malignant catarrhal fever virus alcelaphine herpesvirus 1. Virology. 2024, 590:109958. 10.1016/j.virol.2023.109958", "volume": "590", "year": "2024" }, { "DOI": "10.3390/microorganisms8030409", "article-title": "Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication", "author": "Raza S", "doi-asserted-by": "publisher", "journal-title": "Microorganisms", "key": "ref62", "unstructured": "Raza S, Shahin F, Zhai W, et al.. Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication. Microorganisms. 2020, 8:10.3390/microorganisms8030409", "volume": "8", "year": "2020" }, { "DOI": "10.1093/qjmed/hcab247", "article-title": "Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis", "author": "Deng J", "doi-asserted-by": "publisher", "journal-title": "QJM", "key": "ref63", "unstructured": "Deng J, Zhou F, Ali S, Heybati K, Hou W, Huang E, Wong CY. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021, 114:721-32. 10.1093/qjmed/hcab247", "volume": "114", "year": "2021" }, { "DOI": "10.1186/s12879-022-07589-8", "article-title": "Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype", "author": "Marcolino MS", "doi-asserted-by": "publisher", "journal-title": "BMC Infect Dis", "key": "ref64", "unstructured": "Marcolino MS, Meira KC, Guimarães NS, et al.. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis. 2022, 22:639. 10.1186/s12879-022-07589-8", "volume": "22", "year": "2022" }, { "DOI": "10.1002/jcph.2178", "article-title": "Ivermectin’s role in the prevention of COVID-19: a systematic review and meta-analysis", "author": "Hu GY", "doi-asserted-by": "publisher", "journal-title": "J Clin Pharmacol", "key": "ref65", "unstructured": "Hu GY, Liang CA, Lin PC, Lin CY. Ivermectin’s role in the prevention of COVID-19: a systematic review and meta-analysis. J Clin Pharmacol. 2023, 63:288-97. 10.1002/jcph.2178", "volume": "63", "year": "2023" }, { "DOI": "10.2147/DDDT.S308973", "article-title": "Progress in redirecting antiparasitic drugs for cancer treatment", "author": "Huang H", "doi-asserted-by": "publisher", "journal-title": "Drug Des Devel Ther", "key": "ref66", "unstructured": "Huang H, He Q, Guo B, Xu X, Wu Y, Li X. Progress in redirecting antiparasitic drugs for cancer treatment. Drug Des Devel Ther. 2021, 15:2747-67. 10.2147/DDDT.S308973", "volume": "15", "year": "2021" }, { "DOI": "10.1158/0008-5472.CAN-15-2887", "article-title": "Ivermectin induces cytostatic autophagy by blocking the PAK1/AKT axis in breast cancer", "author": "Dou Q", "doi-asserted-by": "publisher", "journal-title": "Cancer Res", "key": "ref67", "unstructured": "Dou Q, Chen HN, Wang K, et al.. Ivermectin induces cytostatic autophagy by blocking the PAK1/AKT axis in breast cancer. Cancer Res. 2016, 76:4457-69. 10.1158/0008-5472.CAN-15-2887", "volume": "76", "year": "2016" }, { "DOI": "10.1007/s00280-023-04589-6", "article-title": "Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells", "author": "Li MY", "doi-asserted-by": "publisher", "journal-title": "Cancer Chemother Pharmacol", "key": "ref68", "unstructured": "Li MY, Zhang J, Lu X, et al.. Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. Cancer Chemother Pharmacol. 2024, 93:41-54. 10.1007/s00280-023-04589-6", "volume": "93", "year": "2024" }, { "DOI": "10.1016/j.bbrc.2016.10.064", "article-title": "Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress", "author": "Liu Y", "doi-asserted-by": "publisher", "journal-title": "Biochem Biophys Res Commun", "key": "ref69", "unstructured": "Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016, 480:415-21. 10.1016/j.bbrc.2016.10.064", "volume": "480", "year": "2016" }, { "DOI": "10.1002/tox.23440", "article-title": "Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation", "author": "Feng Y", "doi-asserted-by": "publisher", "journal-title": "Environ Toxicol", "key": "ref70", "unstructured": "Feng Y, Wang J, Cai B, Bai X, Zhu Y. Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation. Environ Toxicol. 2022, 37:754-64. 10.1002/tox.23440", "volume": "37", "year": "2022" }, { "article-title": "Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines", "author": "Hashimoto H", "journal-title": "Drug Discov Ther", "key": "ref71", "unstructured": "Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther. 2009, 3:243-6.", "volume": "3", "year": "2009" }, { "DOI": "10.1158/1535-7163.MCT-14-0980-T", "article-title": "Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple-negative breast cancer", "author": "Kwon YJ", "doi-asserted-by": "publisher", "journal-title": "Mol Cancer Ther", "key": "ref72", "unstructured": "Kwon YJ, Petrie K, Leibovitch BA, et al.. Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple-negative breast cancer. Mol Cancer Ther. 2015, 14:1824-36. 10.1158/1535-7163.MCT-14-0980-T", "volume": "14", "year": "2015" }, { "DOI": "10.1038/s41582-019-0220-2", "article-title": "Genetic and molecular epidemiology of adult diffuse glioma", "author": "Molinaro AM", "doi-asserted-by": "publisher", "journal-title": "Nat Rev Neurol", "key": "ref73", "unstructured": "Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019, 15:405-17. 10.1038/s41582-019-0220-2", "volume": "15", "year": "2019" }, { "DOI": "10.1042/BSR20192489", "article-title": "Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells", "author": "Liu J", "doi-asserted-by": "publisher", "journal-title": "Biosci Rep", "key": "ref74", "unstructured": "Liu J, Liang H, Chen C, et al.. Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells. Biosci Rep. 2019, 39:10.1042/BSR20192489", "volume": "39", "year": "2019" } ], "reference-count": 74, "references-count": 74, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/223832-ivermectin-a-multifaceted-drug-with-a-potential-beyond-anti-parasitic-therapy" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy", "type": "journal-article" }